Virax Biolabs names Dr. Nigel McCracken as COO

Virax Biolabs announced the appointment of Dr. Nigel McCracken as the company’s COO. Dr. McCracken will succeed Cameron Shaw, who is moving to Virax’s Advisory Board, and will lead the company’s various growth initiatives, including the company’s expected near-term research-use-only launch of ViraxImmune. In addition, Mark Ternouth, Virax’s current Chief Technology Officer, will be joining the company’s Board of Directors. Ternouth brings decades of experience with companies such as KPMG, PricewaterhouseCoopers, COLT Telecom, John Lewis Partnership and the United Kingdom’s Home Office and Ministry of Justice.